Sunitinib

CHICAGO — Deeper response to treatment was associated with improved progression-free and overall survival in patients with advanced renal cell carcinoma, according to data from the CheckMate 9ER trial.

Ripretinib did not extend PFS compared with sunitinib for patients with advanced gastrointestinal stromal tumor who previously received imatinib, according to randomized phase 3 study results presented during the ASCO Plenary Series.

Nivolumab plus cabozantinib conferred superior PFS, OS and response rates compared with sunitinib as a first-line treatment for advanced renal cell carcinoma, according to results of a phase 3 study presented at ESMO Virtual Congress 2020.

Cytoreductive nephrectomy may extend OS for a well-selected population of patients with metastatic renal cell carcinoma, according to study results published in Cancer.